Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | ROS1 |
Variant | S1986F |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ROS1 S1986F lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986F has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242, PMID: 29333528, PMID: 32776005), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2022). |
Associated Drug Resistance | Y |
Transcript | NM_002944.2 |
gDNA | chr6:g.117318236G>A |
cDNA | c.5957C>T |
Protein | p.S1986F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002944.2 | chr6:g.117318236G>A | c.5957C>T | p.S1986F | RefSeq | GRCh38/hg38 |
NM_002944 | chr6:g.117318236G>A | c.5957C>T | p.S1986F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 S1986F | Advanced Solid Tumor | predicted - sensitive | Lorlatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lorbrena (lorlatinib) inhibited kinase activity of a transformed cell line expressing ROS1 S1986F in culture (PMID: 32918045). | 32918045 |
ROS1 S1986F | Advanced Solid Tumor | predicted - sensitive | SAF-189s | Preclinical - Biochemical | Actionable | In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 S1986F in culture (PMID: 32918045). | 32918045 |
ROS1 fusion ROS1 S1986F ROS1 L2000V | lung non-small cell carcinoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with non-small cell lung cancer harboring a ROS1 fusion who had progressed on Xalkori (crizotinib) was subsequently treated with Lorbrena (lorlatinib) but progression ensued and post treatment biopsy revealed acquisition of ROS1 S1986F and ROS1 L2000V (PMID: 33685866). | 33685866 |
Molecular Profile | Protein Effect | Treatment Approaches |
---|---|---|
ROS1 S1986F | unknown | |
ROS1 fusion ROS1 S1986F ROS1 L2000V |